Literature DB >> 21618503

Cancer immunotherapy: Progress and challenges in the clinical setting.

Hassane M Zarour1, Soldano Ferrone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21618503      PMCID： PMC3426035          DOI： 10.1002/eji.201190035

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


× No keyword cloud information.
  61 in total

Review 1.  A new era for cancer immunotherapy based on the genes that encode cancer antigens.

Authors:  S A Rosenberg
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

Review 2.  HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?

Authors:  Chien-Chung Chang; Michael Campoli; Soldano Ferrone
Journal:  Curr Opin Immunol       Date:  2004-10       Impact factor: 7.486

Review 3.  Functional and clinical relevance of chondroitin sulfate proteoglycan 4.

Authors:  Michael Campoli; Soldano Ferrone; Xinhui Wang
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 4.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

Review 5.  Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

Authors:  Chien-Chung Chang; Michael Campoli; Soldano Ferrone
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

Review 6.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

7.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 8.  Immune infiltration in human cancer: prognostic significance and disease control.

Authors:  Wolf H Fridman; Jérome Galon; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Sylvain Fisson; Diane Damotte; Franck Pagès; Eric Tartour; Catherine Sautès-Fridman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 9.  Improving cancer immunotherapy by targeting tumor-induced immune suppression.

Authors:  Trina J Stewart; Mark J Smyth
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

10.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Authors:  Daniel E Speiser; Danielle Liénard; Nathalie Rufer; Verena Rubio-Godoy; Donata Rimoldi; Ferdy Lejeune; Arthur M Krieg; Jean-Charles Cerottini; Pedro Romero
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808
View more
  9 in total

Review 1.  Gene therapy as a potential tool for treating neuroblastoma-a focused review.

Authors:  M D Kumar; A Dravid; A Kumar; D Sen
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

2.  Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.

Authors:  Satiro Nakamura De Oliveira; Christine Ryan; Francesca Giannoni; Cinnamon L Hardee; Irena Tremcinska; Behrod Katebian; Jennifer Wherley; Arineh Sahaghian; Andy Tu; Tristan Grogan; David Elashoff; Laurence J N Cooper; Roger P Hollis; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2013-10       Impact factor: 5.695

3.  Immunotherapy of genitourinary malignancies.

Authors:  Teruo Inamoto; Haruhito Azuma
Journal:  J Oncol       Date:  2012-03-05       Impact factor: 4.375

4.  The effect of interleukin 36 gene therapy in the regression of tumor.

Authors:  Shiva Solahaye-Kahnamouii; Farrokh Farhadi; Mahni Rahkare-Farshi; Farzaneh Pakdel; Atabak Kashefimehr; Firouz Pouralibaba; Gholamreza Shirani; Mohammad Bayat; Abbas Karimi
Journal:  Iran J Cancer Prev       Date:  2014

5.  BAP31, a promising target for the immunotherapy of malignant melanomas.

Authors:  Shaojuan Yu; Fuli Wang; Li Fan; Yuying Wei; Haitao Li; Yuanjie Sun; Angang Yang; Boquan Jin; Chaojun Song; Kun Yang
Journal:  J Exp Clin Cancer Res       Date:  2015-04-18

6.  Gene therapy based on interleukin-12 loaded chitosan nanoparticles in a mouse model of fibrosarcoma.

Authors:  Saiedeh Razi Soofiyani; Somayeh Hallaj-Nezhadi; Farzaneh Lotfipour; Akbar Mohammad Hosseini; Behzad Baradaran
Journal:  Iran J Basic Med Sci       Date:  2016-11       Impact factor: 2.699

Review 7.  Taming Tumor Glycolysis and Potential Implications for Immunotherapy.

Authors:  Shanmugasundaram Ganapathy-Kanniappan
Journal:  Front Oncol       Date:  2017-03-13       Impact factor: 6.244

8.  Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma.

Authors:  Shiyong Xin; Xianchao Sun; Liang Jin; Zhen Zhou; Xiang Liu; Weiyi Li; Wangli Mei; Jiaxin Zhang; Bihui Zhang; Xudong Yao; Liqing Zhou; Lin Ye
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

9.  Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo.

Authors:  Jun Zhang; Jian-min Yang; Hui-ju Wang; Guo-qing Ru; Dai-ming Fan
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.